| 1 | observational | 8,411 |
| 2 | field-validation | 26 |
| 3 | pharmacoepidemiologic | 24 |
| 4 | ps-based | 14 |
| 5 | qeo | 10 |
| 6 | videourodynamic | 10 |
| 7 | high-weight | 8 |
| 8 | pbe-cpi | 8 |
| 9 | nonadult | 6 |
| 10 | bias.no | 5 |
| 11 | chronometric | 5 |
| 12 | jmen | 5 |
| 13 | mediplus | 5 |
| 14 | observation-based | 5 |
| 15 | powerball | 5 |
| 16 | ambispective | 4 |
| 17 | pharmacokinetic-based | 4 |
| 18 | reproduction-toxicology | 4 |
| 19 | study-birth | 4 |
| 20 | 'well-defined | 3 |
| 21 | 0522 | 3 |
| 22 | amitriptyline-controlled | 3 |
| 23 | bias.two | 3 |
| 24 | cohort-controlled | 3 |
| 25 | cv-outcome | 3 |
| 26 | dorema | 3 |
| 27 | dose-ascending | 3 |
| 28 | hard-endpoint | 3 |
| 29 | internationally-based | 3 |
| 30 | observational-study | 3 |
| 31 | one-armed | 3 |
| 32 | podonet | 3 |
| 33 | trials/prospective | 3 |
| 34 | unrandomised | 3 |
| 35 | analysis.few | 2 |
| 36 | arranges | 2 |
| 37 | biobank-based | 2 |
| 38 | caregivers.the | 2 |
| 39 | cases-series | 2 |
| 40 | clinico-genetic | 2 |
| 41 | colonoscopist-blinded | 2 |
| 42 | cost-evaluation | 2 |
| 43 | experimental/quasi-experimental | 2 |
| 44 | fluphenazine-lai | 2 |
| 45 | full-paper | 2 |
| 46 | gelf-94 | 2 |
| 47 | group-controlled | 2 |
| 48 | high-assurance | 2 |
| 49 | metaproteomic | 2 |
| 50 | morbidity-added | 2 |
| 51 | msl-109 | 2 |
| 52 | multiple-herb | 2 |
| 53 | nanospect/ct | 2 |
| 54 | non-experimental/ethnographic | 2 |
| 55 | placebo-based/comparative | 2 |
| 56 | sponge/diaphragm | 2 |
| 57 | study-kindergarten | 2 |
| 58 | testing.the | 2 |
| 59 | treatment-to-target | 2 |
| 60 | æsop-10 | 2 |
| 61 | 12,691 | 1 |
| 62 | 12.two | 1 |
| 63 | 1:2-matched | 1 |
| 64 | 2,794 | 1 |
| 65 | 2010.this | 1 |
| 66 | 2015.few | 1 |
| 67 | 21,643 | 1 |
| 68 | 24,023 | 1 |
| 69 | 3,062 | 1 |
| 70 | 6185 | 1 |
| 71 | 762-published | 1 |
| 72 | 8,396 | 1 |
| 73 | 8,520 | 1 |
| 74 | a5001/allrt | 1 |
| 75 | abscg-6 | 1 |
| 76 | absenteeism.most | 1 |
| 77 | absenteeism.three | 1 |
| 78 | acenocoumarol/phenprocoumon | 1 |
| 79 | adolescence.seventeen | 1 |
| 80 | adult-only | 1 |
| 81 | advance-ccb | 1 |
| 82 | age-birth | 1 |
| 83 | already-active | 1 |
| 84 | alternate-month | 1 |
| 85 | analytic-cross | 1 |
| 86 | animal/microbial | 1 |
| 87 | antimicrobial-susceptibility | 1 |
| 88 | aortographic | 1 |
| 89 | apricot-ii | 1 |
| 90 | argatroban-915 | 1 |
| 91 | arts-ii | 1 |
| 92 | autopsy-based | 1 |
| 93 | autopsy/post-mortem | 1 |
| 94 | bacteremia/sepsis.this | 1 |
| 95 | behavioral-driven | 1 |
| 96 | best+icd | 1 |
| 97 | bezafibrate-based | 1 |
| 98 | bf.seven | 1 |
| 99 | bias.eleven | 1 |
| 100 | bias.four | 1 |
| 101 | bio-pharmacological | 1 |
| 102 | biochemomics | 1 |
| 103 | biomarker-modulation | 1 |
| 104 | biomedicinal | 1 |
| 105 | blank-controlled | 1 |
| 106 | brunsvigia | 1 |
| 107 | cancer-survivorship | 1 |
| 108 | case-comparison | 1 |
| 109 | case-register | 1 |
| 110 | characteristics.this | 1 |
| 111 | child.this | 1 |
| 112 | chinese-based | 1 |
| 113 | clinical-controlled | 1 |
| 114 | clinico-catamnestic | 1 |
| 115 | cluster-allocated | 1 |
| 116 | co-labeling | 1 |
| 117 | color-doppler-echocardiographic | 1 |
| 118 | computer-docking | 1 |
| 119 | condyloma.four | 1 |
| 120 | controlled-exposure | 1 |
| 121 | controlled-outcome | 1 |
| 122 | copd-ps+copd-6 | 1 |
| 123 | corticosteroid-salmeterol | 1 |
| 124 | cost-effectiviness | 1 |
| 125 | cost/burden-of-illness | 1 |
| 126 | costing/resource-use | 1 |
| 127 | cue-induction | 1 |
| 128 | cystomanometric | 1 |
| 129 | dcct-edic | 1 |
| 130 | decay-phase | 1 |
| 131 | delivery/retention | 1 |
| 132 | dermatopharmacokinetic | 1 |
| 133 | design-a | 1 |
| 134 | design-associated | 1 |
| 135 | diabetes-botnia | 1 |
| 136 | dna-sequence | 1 |
| 137 | dose-conversion | 1 |
| 138 | drugs.three | 1 |
| 139 | early-appearing | 1 |
| 140 | ecopathological | 1 |
| 141 | effectiveness-observational | 1 |
| 142 | em-related | 1 |
| 143 | emipirical | 1 |
| 144 | end-feel | 1 |
| 145 | environmental-epidemiological | 1 |
| 146 | epcs.this | 1 |
| 147 | epidemiologic/clinical | 1 |
| 148 | epidemiological/observational | 1 |
| 149 | epidemiology/observation | 1 |
| 150 | epilepsy.three | 1 |
| 151 | episode-inception | 1 |
| 152 | experimentally-controlled | 1 |
| 153 | external-validation | 1 |
| 154 | family-genetic | 1 |
| 155 | feminists/social | 1 |
| 156 | finn-home | 1 |
| 157 | five.five | 1 |
| 158 | food-reinforced | 1 |
| 159 | forteen | 1 |
| 160 | four-city | 1 |
| 161 | freelisted | 1 |
| 162 | function.three | 1 |
| 163 | gamma-scintigraphic | 1 |
| 164 | gastrograffin | 1 |
| 165 | general-response | 1 |
| 166 | genomic/genetic | 1 |
| 167 | geoherbs | 1 |
| 168 | gercod-sponsored | 1 |
| 169 | groups.four | 1 |
| 170 | hepatopathogical | 1 |
| 171 | human-controlled | 1 |
| 172 | hypercholesterolemia-matched | 1 |
| 173 | hyperthermia-polymerase | 1 |
| 174 | ianua | 1 |
| 175 | ifn-placebo | 1 |
| 176 | imaging/biodistribution | 1 |
| 177 | imagiological | 1 |
| 178 | imipramine-controlled | 1 |
| 179 | immunofluoresecnce | 1 |
| 180 | importance.further | 1 |
| 181 | in-deep | 1 |
| 182 | inappropriate/unextractable | 1 |
| 183 | inceptional | 1 |
| 184 | infant.future | 1 |
| 185 | initial-velocity | 1 |
| 186 | inter-author | 1 |
| 187 | intervention/clinical | 1 |
| 188 | interventionsand | 1 |
| 189 | ism-based | 1 |
| 190 | j-core | 1 |
| 191 | kill-curve | 1 |
| 192 | large-cohort | 1 |
| 193 | less.no | 1 |
| 194 | life.six | 1 |
| 195 | lifethree | 1 |
| 196 | lipid-interaction | 1 |
| 197 | livestock-related | 1 |
| 198 | longer.no | 1 |
| 199 | lymphangiectasia.the | 1 |
| 200 | macrofilarial | 1 |
| 201 | medical-ethnobotanical | 1 |
| 202 | meso-level | 1 |
| 203 | methylnaltrexone.in | 1 |
| 204 | microindentation | 1 |
| 205 | mid-to-high-quality | 1 |
| 206 | middle/late-phase | 1 |
| 207 | ml/hour.one | 1 |
| 208 | mono-intervention | 1 |
| 209 | mono-user | 1 |
| 210 | months.all | 1 |
| 211 | months.main | 1 |
| 212 | months.two | 1 |
| 213 | mortality.human | 1 |
| 214 | multi-operator | 1 |
| 215 | multicenter-based | 1 |
| 216 | multicentere | 1 |
| 217 | multiendoscopist | 1 |
| 218 | mycochemical | 1 |
| 219 | nanospect | 1 |
| 220 | nct00275834 | 1 |
| 221 | necosad | 1 |
| 222 | neuriomaging | 1 |
| 223 | newborn-screening | 1 |
| 224 | nimh-supported | 1 |
| 225 | nitrogen-balance | 1 |
| 226 | non-burping | 1 |
| 227 | non-industry-supported | 1 |
| 228 | non-longitudinal | 1 |
| 229 | non-population-based | 1 |
| 230 | non-randomised/observational | 1 |
| 231 | non-source | 1 |
| 232 | nonfunded | 1 |
| 233 | nonsurgical.the | 1 |
| 234 | not.more | 1 |
| 235 | nutrition-italy | 1 |
| 236 | nutrition-spain | 1 |
| 237 | obervational | 1 |
| 238 | obesity-drug | 1 |
| 239 | observational/descriptive | 1 |
| 240 | observationnal | 1 |
| 241 | ocay | 1 |
| 242 | office-practice-based | 1 |
| 243 | ok04 | 1 |
| 244 | ongoing/further | 1 |
| 245 | open-enrolment | 1 |
| 246 | open-observational | 1 |
| 247 | organism-level | 1 |
| 248 | organism.laboratory | 1 |
| 249 | orginal | 1 |
| 250 | outcome.no | 1 |
| 251 | outcomes.six | 1 |
| 252 | outcomes.thirty | 1 |
| 253 | palaeoclimate | 1 |
| 254 | parallel-run | 1 |
| 255 | pattern/diagnosis | 1 |
| 256 | peptide-mapping | 1 |
| 257 | peri-/postnatal | 1 |
| 258 | peritonitis-three | 1 |
| 259 | pet.two | 1 |
| 260 | pharmaceutical-funded | 1 |
| 261 | pharmaco-economical | 1 |
| 262 | pharmaco-epidemiologic | 1 |
| 263 | pharmaco-scintigraphic | 1 |
| 264 | phonoechocardiographic | 1 |
| 265 | photosensitivity-prevention | 1 |
| 266 | physi-cians | 1 |
| 267 | placebo.fifteen | 1 |
| 268 | polariscopic | 1 |
| 269 | possible.sixteen | 1 |
| 270 | post-denervation | 1 |
| 271 | post-stricta | 1 |
| 272 | postobservational | 1 |
| 273 | pre-1989 | 1 |
| 274 | pre-clinic | 1 |
| 275 | pregnancy.five | 1 |
| 276 | preparations.many | 1 |
| 277 | pressure-perfusion | 1 |
| 278 | professionalno | 1 |
| 279 | prospective/observational | 1 |
| 280 | proteo-genomic | 1 |
| 281 | psychoneuroimmunologic | 1 |
| 282 | radio-isotope | 1 |
| 283 | radiopharmacological | 1 |
| 284 | regw | 1 |
| 285 | reliever.two | 1 |
| 286 | remission.one | 1 |
| 287 | research/laboratory | 1 |
| 288 | restricted-area | 1 |
| 289 | retrospective-cohort | 1 |
| 290 | retrospective-controlled | 1 |
| 291 | retrospectively-selected | 1 |
| 292 | risk-relation | 1 |
| 293 | risperidone.three | 1 |
| 294 | rituxvasc | 1 |
| 295 | sage-based | 1 |
| 296 | same-centre | 1 |
| 297 | sedimentological | 1 |
| 298 | senorx | 1 |
| 299 | separate-day | 1 |
| 300 | sepstwo | 1 |
| 301 | sequential-analysis | 1 |
| 302 | settings.recent | 1 |
| 303 | sheffe | 1 |
| 304 | single-cases | 1 |
| 305 | single-photon-counting | 1 |
| 306 | sino-monica | 1 |
| 307 | site-of-absorption | 1 |
| 308 | six-egg | 1 |
| 309 | sleep-curtailment | 1 |
| 310 | socio-technical | 1 |
| 311 | sound-c1 | 1 |
| 312 | speed.two | 1 |
| 313 | staytwo | 1 |
| 314 | stressful-event-focused | 1 |
| 315 | studies.eight | 1 |
| 316 | studies.few | 1 |
| 317 | studies.five | 1 |
| 318 | studies.three | 1 |
| 319 | survey-birth | 1 |
| 320 | symptom-mapping | 1 |
| 321 | syndromological | 1 |
| 322 | tca-controlled | 1 |
| 323 | teae-related | 1 |
| 324 | telemetry-upgrade | 1 |
| 325 | teletransmitted | 1 |
| 326 | therapy-development | 1 |
| 327 | tional | 1 |
| 328 | toxicometric | 1 |
| 329 | transconjugation | 1 |
| 330 | trauma.one | 1 |
| 331 | treatment-pathway | 1 |
| 332 | tumor-labeling | 1 |
| 333 | turkic | 1 |
| 334 | unblinded/unpublished | 1 |
| 335 | unclear.most | 1 |
| 336 | uncontrolled/cohort | 1 |
| 337 | uro-dynamic | 1 |
| 338 | use.this | 1 |
| 339 | usual.all | 1 |
| 340 | vaers-based | 1 |
| 341 | varenicline.two | 1 |
| 342 | veev-reactive | 1 |
| 343 | vf/off | 1 |
| 344 | well-stratified | 1 |
| 1 | 'well-defined | 3 |
| 2 | 0522 | 3 |
| 3 | 12,691 | 1 |
| 4 | 12.two | 1 |
| 5 | 1:2-matched | 1 |
| 6 | 2,794 | 1 |
| 7 | 2010.this | 1 |
| 8 | 2015.few | 1 |
| 9 | 21,643 | 1 |
| 10 | 24,023 | 1 |
| 11 | 3,062 | 1 |
| 12 | 6185 | 1 |
| 13 | 762-published | 1 |
| 14 | 8,396 | 1 |
| 15 | 8,520 | 1 |
| 16 | a5001/allrt | 1 |
| 17 | abscg-6 | 1 |
| 18 | absenteeism.most | 1 |
| 19 | absenteeism.three | 1 |
| 20 | acenocoumarol/phenprocoumon | 1 |
| 21 | adolescence.seventeen | 1 |
| 22 | adult-only | 1 |
| 23 | advance-ccb | 1 |
| 24 | age-birth | 1 |
| 25 | already-active | 1 |
| 26 | alternate-month | 1 |
| 27 | ambispective | 4 |
| 28 | amitriptyline-controlled | 3 |
| 29 | analysis.few | 2 |
| 30 | analytic-cross | 1 |
| 31 | animal/microbial | 1 |
| 32 | antimicrobial-susceptibility | 1 |
| 33 | aortographic | 1 |
| 34 | apricot-ii | 1 |
| 35 | argatroban-915 | 1 |
| 36 | arranges | 2 |
| 37 | arts-ii | 1 |
| 38 | autopsy-based | 1 |
| 39 | autopsy/post-mortem | 1 |
| 40 | bacteremia/sepsis.this | 1 |
| 41 | behavioral-driven | 1 |
| 42 | best+icd | 1 |
| 43 | bezafibrate-based | 1 |
| 44 | bf.seven | 1 |
| 45 | bias.eleven | 1 |
| 46 | bias.four | 1 |
| 47 | bias.no | 5 |
| 48 | bias.two | 3 |
| 49 | bio-pharmacological | 1 |
| 50 | biobank-based | 2 |
| 51 | biochemomics | 1 |
| 52 | biomarker-modulation | 1 |
| 53 | biomedicinal | 1 |
| 54 | blank-controlled | 1 |
| 55 | brunsvigia | 1 |
| 56 | cancer-survivorship | 1 |
| 57 | caregivers.the | 2 |
| 58 | case-comparison | 1 |
| 59 | case-register | 1 |
| 60 | cases-series | 2 |
| 61 | characteristics.this | 1 |
| 62 | child.this | 1 |
| 63 | chinese-based | 1 |
| 64 | chronometric | 5 |
| 65 | clinical-controlled | 1 |
| 66 | clinico-catamnestic | 1 |
| 67 | clinico-genetic | 2 |
| 68 | cluster-allocated | 1 |
| 69 | co-labeling | 1 |
| 70 | cohort-controlled | 3 |
| 71 | colonoscopist-blinded | 2 |
| 72 | color-doppler-echocardiographic | 1 |
| 73 | computer-docking | 1 |
| 74 | condyloma.four | 1 |
| 75 | controlled-exposure | 1 |
| 76 | controlled-outcome | 1 |
| 77 | copd-ps+copd-6 | 1 |
| 78 | corticosteroid-salmeterol | 1 |
| 79 | cost-effectiviness | 1 |
| 80 | cost-evaluation | 2 |
| 81 | cost/burden-of-illness | 1 |
| 82 | costing/resource-use | 1 |
| 83 | cue-induction | 1 |
| 84 | cv-outcome | 3 |
| 85 | cystomanometric | 1 |
| 86 | dcct-edic | 1 |
| 87 | decay-phase | 1 |
| 88 | delivery/retention | 1 |
| 89 | dermatopharmacokinetic | 1 |
| 90 | design-a | 1 |
| 91 | design-associated | 1 |
| 92 | diabetes-botnia | 1 |
| 93 | dna-sequence | 1 |
| 94 | dorema | 3 |
| 95 | dose-ascending | 3 |
| 96 | dose-conversion | 1 |
| 97 | drugs.three | 1 |
| 98 | early-appearing | 1 |
| 99 | ecopathological | 1 |
| 100 | effectiveness-observational | 1 |
| 101 | em-related | 1 |
| 102 | emipirical | 1 |
| 103 | end-feel | 1 |
| 104 | environmental-epidemiological | 1 |
| 105 | epcs.this | 1 |
| 106 | epidemiologic/clinical | 1 |
| 107 | epidemiological/observational | 1 |
| 108 | epidemiology/observation | 1 |
| 109 | epilepsy.three | 1 |
| 110 | episode-inception | 1 |
| 111 | experimental/quasi-experimental | 2 |
| 112 | experimentally-controlled | 1 |
| 113 | external-validation | 1 |
| 114 | family-genetic | 1 |
| 115 | feminists/social | 1 |
| 116 | field-validation | 26 |
| 117 | finn-home | 1 |
| 118 | five.five | 1 |
| 119 | fluphenazine-lai | 2 |
| 120 | food-reinforced | 1 |
| 121 | forteen | 1 |
| 122 | four-city | 1 |
| 123 | freelisted | 1 |
| 124 | full-paper | 2 |
| 125 | function.three | 1 |
| 126 | gamma-scintigraphic | 1 |
| 127 | gastrograffin | 1 |
| 128 | gelf-94 | 2 |
| 129 | general-response | 1 |
| 130 | genomic/genetic | 1 |
| 131 | geoherbs | 1 |
| 132 | gercod-sponsored | 1 |
| 133 | group-controlled | 2 |
| 134 | groups.four | 1 |
| 135 | hard-endpoint | 3 |
| 136 | hepatopathogical | 1 |
| 137 | high-assurance | 2 |
| 138 | high-weight | 8 |
| 139 | human-controlled | 1 |
| 140 | hypercholesterolemia-matched | 1 |
| 141 | hyperthermia-polymerase | 1 |
| 142 | ianua | 1 |
| 143 | ifn-placebo | 1 |
| 144 | imaging/biodistribution | 1 |
| 145 | imagiological | 1 |
| 146 | imipramine-controlled | 1 |
| 147 | immunofluoresecnce | 1 |
| 148 | importance.further | 1 |
| 149 | in-deep | 1 |
| 150 | inappropriate/unextractable | 1 |
| 151 | inceptional | 1 |
| 152 | infant.future | 1 |
| 153 | initial-velocity | 1 |
| 154 | inter-author | 1 |
| 155 | internationally-based | 3 |
| 156 | intervention/clinical | 1 |
| 157 | interventionsand | 1 |
| 158 | ism-based | 1 |
| 159 | j-core | 1 |
| 160 | jmen | 5 |
| 161 | kill-curve | 1 |
| 162 | large-cohort | 1 |
| 163 | less.no | 1 |
| 164 | life.six | 1 |
| 165 | lifethree | 1 |
| 166 | lipid-interaction | 1 |
| 167 | livestock-related | 1 |
| 168 | longer.no | 1 |
| 169 | lymphangiectasia.the | 1 |
| 170 | macrofilarial | 1 |
| 171 | medical-ethnobotanical | 1 |
| 172 | mediplus | 5 |
| 173 | meso-level | 1 |
| 174 | metaproteomic | 2 |
| 175 | methylnaltrexone.in | 1 |
| 176 | microindentation | 1 |
| 177 | mid-to-high-quality | 1 |
| 178 | middle/late-phase | 1 |
| 179 | ml/hour.one | 1 |
| 180 | mono-intervention | 1 |
| 181 | mono-user | 1 |
| 182 | months.all | 1 |
| 183 | months.main | 1 |
| 184 | months.two | 1 |
| 185 | morbidity-added | 2 |
| 186 | mortality.human | 1 |
| 187 | msl-109 | 2 |
| 188 | multi-operator | 1 |
| 189 | multicenter-based | 1 |
| 190 | multicentere | 1 |
| 191 | multiendoscopist | 1 |
| 192 | multiple-herb | 2 |
| 193 | mycochemical | 1 |
| 194 | nanospect | 1 |
| 195 | nanospect/ct | 2 |
| 196 | nct00275834 | 1 |
| 197 | necosad | 1 |
| 198 | neuriomaging | 1 |
| 199 | newborn-screening | 1 |
| 200 | nimh-supported | 1 |
| 201 | nitrogen-balance | 1 |
| 202 | non-burping | 1 |
| 203 | non-experimental/ethnographic | 2 |
| 204 | non-industry-supported | 1 |
| 205 | non-longitudinal | 1 |
| 206 | non-population-based | 1 |
| 207 | non-randomised/observational | 1 |
| 208 | non-source | 1 |
| 209 | nonadult | 6 |
| 210 | nonfunded | 1 |
| 211 | nonsurgical.the | 1 |
| 212 | not.more | 1 |
| 213 | nutrition-italy | 1 |
| 214 | nutrition-spain | 1 |
| 215 | obervational | 1 |
| 216 | obesity-drug | 1 |
| 217 | observation-based | 5 |
| 218 | observational | 8,411 |
| 219 | observational-study | 3 |
| 220 | observational/descriptive | 1 |
| 221 | observationnal | 1 |
| 222 | ocay | 1 |
| 223 | office-practice-based | 1 |
| 224 | ok04 | 1 |
| 225 | one-armed | 3 |
| 226 | ongoing/further | 1 |
| 227 | open-enrolment | 1 |
| 228 | open-observational | 1 |
| 229 | organism-level | 1 |
| 230 | organism.laboratory | 1 |
| 231 | orginal | 1 |
| 232 | outcome.no | 1 |
| 233 | outcomes.six | 1 |
| 234 | outcomes.thirty | 1 |
| 235 | palaeoclimate | 1 |
| 236 | parallel-run | 1 |
| 237 | pattern/diagnosis | 1 |
| 238 | pbe-cpi | 8 |
| 239 | peptide-mapping | 1 |
| 240 | peri-/postnatal | 1 |
| 241 | peritonitis-three | 1 |
| 242 | pet.two | 1 |
| 243 | pharmaceutical-funded | 1 |
| 244 | pharmaco-economical | 1 |
| 245 | pharmaco-epidemiologic | 1 |
| 246 | pharmaco-scintigraphic | 1 |
| 247 | pharmacoepidemiologic | 24 |
| 248 | pharmacokinetic-based | 4 |
| 249 | phonoechocardiographic | 1 |
| 250 | photosensitivity-prevention | 1 |
| 251 | physi-cians | 1 |
| 252 | placebo-based/comparative | 2 |
| 253 | placebo.fifteen | 1 |
| 254 | podonet | 3 |
| 255 | polariscopic | 1 |
| 256 | possible.sixteen | 1 |
| 257 | post-denervation | 1 |
| 258 | post-stricta | 1 |
| 259 | postobservational | 1 |
| 260 | powerball | 5 |
| 261 | pre-1989 | 1 |
| 262 | pre-clinic | 1 |
| 263 | pregnancy.five | 1 |
| 264 | preparations.many | 1 |
| 265 | pressure-perfusion | 1 |
| 266 | professionalno | 1 |
| 267 | prospective/observational | 1 |
| 268 | proteo-genomic | 1 |
| 269 | ps-based | 14 |
| 270 | psychoneuroimmunologic | 1 |
| 271 | qeo | 10 |
| 272 | radio-isotope | 1 |
| 273 | radiopharmacological | 1 |
| 274 | regw | 1 |
| 275 | reliever.two | 1 |
| 276 | remission.one | 1 |
| 277 | reproduction-toxicology | 4 |
| 278 | research/laboratory | 1 |
| 279 | restricted-area | 1 |
| 280 | retrospective-cohort | 1 |
| 281 | retrospective-controlled | 1 |
| 282 | retrospectively-selected | 1 |
| 283 | risk-relation | 1 |
| 284 | risperidone.three | 1 |
| 285 | rituxvasc | 1 |
| 286 | sage-based | 1 |
| 287 | same-centre | 1 |
| 288 | sedimentological | 1 |
| 289 | senorx | 1 |
| 290 | separate-day | 1 |
| 291 | sepstwo | 1 |
| 292 | sequential-analysis | 1 |
| 293 | settings.recent | 1 |
| 294 | sheffe | 1 |
| 295 | single-cases | 1 |
| 296 | single-photon-counting | 1 |
| 297 | sino-monica | 1 |
| 298 | site-of-absorption | 1 |
| 299 | six-egg | 1 |
| 300 | sleep-curtailment | 1 |
| 301 | socio-technical | 1 |
| 302 | sound-c1 | 1 |
| 303 | speed.two | 1 |
| 304 | sponge/diaphragm | 2 |
| 305 | staytwo | 1 |
| 306 | stressful-event-focused | 1 |
| 307 | studies.eight | 1 |
| 308 | studies.few | 1 |
| 309 | studies.five | 1 |
| 310 | studies.three | 1 |
| 311 | study-birth | 4 |
| 312 | study-kindergarten | 2 |
| 313 | survey-birth | 1 |
| 314 | symptom-mapping | 1 |
| 315 | syndromological | 1 |
| 316 | tca-controlled | 1 |
| 317 | teae-related | 1 |
| 318 | telemetry-upgrade | 1 |
| 319 | teletransmitted | 1 |
| 320 | testing.the | 2 |
| 321 | therapy-development | 1 |
| 322 | tional | 1 |
| 323 | toxicometric | 1 |
| 324 | transconjugation | 1 |
| 325 | trauma.one | 1 |
| 326 | treatment-pathway | 1 |
| 327 | treatment-to-target | 2 |
| 328 | trials/prospective | 3 |
| 329 | tumor-labeling | 1 |
| 330 | turkic | 1 |
| 331 | unblinded/unpublished | 1 |
| 332 | unclear.most | 1 |
| 333 | uncontrolled/cohort | 1 |
| 334 | unrandomised | 3 |
| 335 | uro-dynamic | 1 |
| 336 | use.this | 1 |
| 337 | usual.all | 1 |
| 338 | vaers-based | 1 |
| 339 | varenicline.two | 1 |
| 340 | veev-reactive | 1 |
| 341 | vf/off | 1 |
| 342 | videourodynamic | 10 |
| 343 | well-stratified | 1 |
| 344 | æsop-10 | 2 |
| 1 | æsop-10 | 2 |
| 2 | 8,520 | 1 |
| 3 | 12,691 | 1 |
| 4 | sound-c1 | 1 |
| 5 | 0522 | 3 |
| 6 | 3,062 | 1 |
| 7 | 24,023 | 1 |
| 8 | 21,643 | 1 |
| 9 | ok04 | 1 |
| 10 | nct00275834 | 1 |
| 11 | gelf-94 | 2 |
| 12 | 2,794 | 1 |
| 13 | argatroban-915 | 1 |
| 14 | 6185 | 1 |
| 15 | copd-ps+copd-6 | 1 |
| 16 | abscg-6 | 1 |
| 17 | 8,396 | 1 |
| 18 | msl-109 | 2 |
| 19 | pre-1989 | 1 |
| 20 | design-a | 1 |
| 21 | sino-monica | 1 |
| 22 | restricted-area | 1 |
| 23 | brunsvigia | 1 |
| 24 | diabetes-botnia | 1 |
| 25 | dorema | 3 |
| 26 | post-stricta | 1 |
| 27 | ianua | 1 |
| 28 | advance-ccb | 1 |
| 29 | multiple-herb | 2 |
| 30 | dcct-edic | 1 |
| 31 | pharmaco-epidemiologic | 1 |
| 32 | pharmacoepidemiologic | 24 |
| 33 | psychoneuroimmunologic | 1 |
| 34 | gamma-scintigraphic | 1 |
| 35 | pharmaco-scintigraphic | 1 |
| 36 | color-doppler-echocardiographic | 1 |
| 37 | phonoechocardiographic | 1 |
| 38 | non-experimental/ethnographic | 2 |
| 39 | aortographic | 1 |
| 40 | turkic | 1 |
| 41 | uro-dynamic | 1 |
| 42 | videourodynamic | 10 |
| 43 | metaproteomic | 2 |
| 44 | proteo-genomic | 1 |
| 45 | pre-clinic | 1 |
| 46 | polariscopic | 1 |
| 47 | toxicometric | 1 |
| 48 | cystomanometric | 1 |
| 49 | chronometric | 5 |
| 50 | clinico-genetic | 2 |
| 51 | family-genetic | 1 |
| 52 | genomic/genetic | 1 |
| 53 | dermatopharmacokinetic | 1 |
| 54 | clinico-catamnestic | 1 |
| 55 | rituxvasc | 1 |
| 56 | necosad | 1 |
| 57 | best+icd | 1 |
| 58 | food-reinforced | 1 |
| 59 | morbidity-added | 2 |
| 60 | colonoscopist-blinded | 2 |
| 61 | pharmaceutical-funded | 1 |
| 62 | nonfunded | 1 |
| 63 | 1:2-matched | 1 |
| 64 | hypercholesterolemia-matched | 1 |
| 65 | 762-published | 1 |
| 66 | unblinded/unpublished | 1 |
| 67 | well-stratified | 1 |
| 68 | tca-controlled | 1 |
| 69 | amitriptyline-controlled | 3 |
| 70 | imipramine-controlled | 1 |
| 71 | retrospective-controlled | 1 |
| 72 | blank-controlled | 1 |
| 73 | clinical-controlled | 1 |
| 74 | human-controlled | 1 |
| 75 | group-controlled | 2 |
| 76 | cohort-controlled | 3 |
| 77 | experimentally-controlled | 1 |
| 78 | one-armed | 3 |
| 79 | 'well-defined | 3 |
| 80 | gercod-sponsored | 1 |
| 81 | pharmacokinetic-based | 4 |
| 82 | office-practice-based | 1 |
| 83 | sage-based | 1 |
| 84 | chinese-based | 1 |
| 85 | bezafibrate-based | 1 |
| 86 | biobank-based | 2 |
| 87 | ism-based | 1 |
| 88 | non-population-based | 1 |
| 89 | observation-based | 5 |
| 90 | multicenter-based | 1 |
| 91 | ps-based | 14 |
| 92 | vaers-based | 1 |
| 93 | internationally-based | 3 |
| 94 | autopsy-based | 1 |
| 95 | unrandomised | 3 |
| 96 | stressful-event-focused | 1 |
| 97 | cluster-allocated | 1 |
| 98 | design-associated | 1 |
| 99 | teae-related | 1 |
| 100 | livestock-related | 1 |
| 101 | em-related | 1 |
| 102 | retrospectively-selected | 1 |
| 103 | nimh-supported | 1 |
| 104 | non-industry-supported | 1 |
| 105 | freelisted | 1 |
| 106 | teletransmitted | 1 |
| 107 | interventionsand | 1 |
| 108 | nitrogen-balance | 1 |
| 109 | high-assurance | 2 |
| 110 | immunofluoresecnce | 1 |
| 111 | dna-sequence | 1 |
| 112 | non-source | 1 |
| 113 | telemetry-upgrade | 1 |
| 114 | peritonitis-three | 1 |
| 115 | risperidone.three | 1 |
| 116 | absenteeism.three | 1 |
| 117 | function.three | 1 |
| 118 | studies.three | 1 |
| 119 | drugs.three | 1 |
| 120 | epilepsy.three | 1 |
| 121 | lifethree | 1 |
| 122 | sheffe | 1 |
| 123 | lymphangiectasia.the | 1 |
| 124 | testing.the | 2 |
| 125 | nonsurgical.the | 1 |
| 126 | caregivers.the | 2 |
| 127 | inappropriate/unextractable | 1 |
| 128 | controlled-outcome | 1 |
| 129 | cv-outcome | 3 |
| 130 | finn-home | 1 |
| 131 | trauma.one | 1 |
| 132 | remission.one | 1 |
| 133 | ml/hour.one | 1 |
| 134 | radio-isotope | 1 |
| 135 | multicentere | 1 |
| 136 | j-core | 1 |
| 137 | not.more | 1 |
| 138 | same-centre | 1 |
| 139 | controlled-exposure | 1 |
| 140 | infant.future | 1 |
| 141 | middle/late-phase | 1 |
| 142 | decay-phase | 1 |
| 143 | hyperthermia-polymerase | 1 |
| 144 | general-response | 1 |
| 145 | costing/resource-use | 1 |
| 146 | palaeoclimate | 1 |
| 147 | five.five | 1 |
| 148 | studies.five | 1 |
| 149 | pregnancy.five | 1 |
| 150 | placebo-based/comparative | 2 |
| 151 | already-active | 1 |
| 152 | veev-reactive | 1 |
| 153 | ambispective | 4 |
| 154 | trials/prospective | 3 |
| 155 | observational/descriptive | 1 |
| 156 | kill-curve | 1 |
| 157 | vf/off | 1 |
| 158 | six-egg | 1 |
| 159 | dose-ascending | 3 |
| 160 | neuriomaging | 1 |
| 161 | computer-docking | 1 |
| 162 | co-labeling | 1 |
| 163 | tumor-labeling | 1 |
| 164 | newborn-screening | 1 |
| 165 | peptide-mapping | 1 |
| 166 | symptom-mapping | 1 |
| 167 | non-burping | 1 |
| 168 | early-appearing | 1 |
| 169 | single-photon-counting | 1 |
| 170 | obesity-drug | 1 |
| 171 | alternate-month | 1 |
| 172 | age-birth | 1 |
| 173 | study-birth | 4 |
| 174 | survey-birth | 1 |
| 175 | fluphenazine-lai | 2 |
| 176 | arts-ii | 1 |
| 177 | apricot-ii | 1 |
| 178 | pbe-cpi | 8 |
| 179 | hepatopathogical | 1 |
| 180 | bio-pharmacological | 1 |
| 181 | radiopharmacological | 1 |
| 182 | ecopathological | 1 |
| 183 | imagiological | 1 |
| 184 | environmental-epidemiological | 1 |
| 185 | syndromological | 1 |
| 186 | sedimentological | 1 |
| 187 | mycochemical | 1 |
| 188 | pharmaco-economical | 1 |
| 189 | medical-ethnobotanical | 1 |
| 190 | socio-technical | 1 |
| 191 | epidemiologic/clinical | 1 |
| 192 | intervention/clinical | 1 |
| 193 | emipirical | 1 |
| 194 | animal/microbial | 1 |
| 195 | feminists/social | 1 |
| 196 | macrofilarial | 1 |
| 197 | biomedicinal | 1 |
| 198 | non-longitudinal | 1 |
| 199 | orginal | 1 |
| 200 | observationnal | 1 |
| 201 | tional | 1 |
| 202 | obervational | 1 |
| 203 | observational | 8,411 |
| 204 | open-observational | 1 |
| 205 | effectiveness-observational | 1 |
| 206 | non-randomised/observational | 1 |
| 207 | prospective/observational | 1 |
| 208 | epidemiological/observational | 1 |
| 209 | postobservational | 1 |
| 210 | inceptional | 1 |
| 211 | peri-/postnatal | 1 |
| 212 | experimental/quasi-experimental | 2 |
| 213 | end-feel | 1 |
| 214 | organism-level | 1 |
| 215 | meso-level | 1 |
| 216 | usual.all | 1 |
| 217 | months.all | 1 |
| 218 | powerball | 5 |
| 219 | corticosteroid-salmeterol | 1 |
| 220 | autopsy/post-mortem | 1 |
| 221 | sponge/diaphragm | 2 |
| 222 | mortality.human | 1 |
| 223 | placebo.fifteen | 1 |
| 224 | adolescence.seventeen | 1 |
| 225 | forteen | 1 |
| 226 | possible.sixteen | 1 |
| 227 | jmen | 5 |
| 228 | study-kindergarten | 2 |
| 229 | bias.eleven | 1 |
| 230 | bf.seven | 1 |
| 231 | behavioral-driven | 1 |
| 232 | methylnaltrexone.in | 1 |
| 233 | months.main | 1 |
| 234 | nutrition-spain | 1 |
| 235 | gastrograffin | 1 |
| 236 | dose-conversion | 1 |
| 237 | pressure-perfusion | 1 |
| 238 | field-validation | 26 |
| 239 | external-validation | 1 |
| 240 | transconjugation | 1 |
| 241 | risk-relation | 1 |
| 242 | biomarker-modulation | 1 |
| 243 | microindentation | 1 |
| 244 | cost-evaluation | 2 |
| 245 | post-denervation | 1 |
| 246 | epidemiology/observation | 1 |
| 247 | lipid-interaction | 1 |
| 248 | cue-induction | 1 |
| 249 | delivery/retention | 1 |
| 250 | photosensitivity-prevention | 1 |
| 251 | mono-intervention | 1 |
| 252 | episode-inception | 1 |
| 253 | site-of-absorption | 1 |
| 254 | imaging/biodistribution | 1 |
| 255 | acenocoumarol/phenprocoumon | 1 |
| 256 | case-comparison | 1 |
| 257 | parallel-run | 1 |
| 258 | ifn-placebo | 1 |
| 259 | qeo | 10 |
| 260 | outcome.no | 1 |
| 261 | longer.no | 1 |
| 262 | bias.no | 5 |
| 263 | less.no | 1 |
| 264 | professionalno | 1 |
| 265 | 12.two | 1 |
| 266 | speed.two | 1 |
| 267 | varenicline.two | 1 |
| 268 | reliever.two | 1 |
| 269 | bias.two | 3 |
| 270 | months.two | 1 |
| 271 | pet.two | 1 |
| 272 | sepstwo | 1 |
| 273 | staytwo | 1 |
| 274 | in-deep | 1 |
| 275 | cancer-survivorship | 1 |
| 276 | importance.further | 1 |
| 277 | ongoing/further | 1 |
| 278 | full-paper | 2 |
| 279 | mono-user | 1 |
| 280 | case-register | 1 |
| 281 | inter-author | 1 |
| 282 | multi-operator | 1 |
| 283 | condyloma.four | 1 |
| 284 | bias.four | 1 |
| 285 | groups.four | 1 |
| 286 | geoherbs | 1 |
| 287 | biochemomics | 1 |
| 288 | arranges | 2 |
| 289 | cases-series | 2 |
| 290 | single-cases | 1 |
| 291 | 2010.this | 1 |
| 292 | child.this | 1 |
| 293 | use.this | 1 |
| 294 | characteristics.this | 1 |
| 295 | epcs.this | 1 |
| 296 | bacteremia/sepsis.this | 1 |
| 297 | pattern/diagnosis | 1 |
| 298 | sequential-analysis | 1 |
| 299 | physi-cians | 1 |
| 300 | cost-effectiviness | 1 |
| 301 | cost/burden-of-illness | 1 |
| 302 | analytic-cross | 1 |
| 303 | mediplus | 5 |
| 304 | nanospect/ct | 2 |
| 305 | nanospect | 1 |
| 306 | treatment-to-target | 2 |
| 307 | podonet | 3 |
| 308 | studies.eight | 1 |
| 309 | high-weight | 8 |
| 310 | nonadult | 6 |
| 311 | settings.recent | 1 |
| 312 | sleep-curtailment | 1 |
| 313 | open-enrolment | 1 |
| 314 | therapy-development | 1 |
| 315 | hard-endpoint | 3 |
| 316 | a5001/allrt | 1 |
| 317 | large-cohort | 1 |
| 318 | retrospective-cohort | 1 |
| 319 | uncontrolled/cohort | 1 |
| 320 | multiendoscopist | 1 |
| 321 | absenteeism.most | 1 |
| 322 | unclear.most | 1 |
| 323 | 2015.few | 1 |
| 324 | studies.few | 1 |
| 325 | analysis.few | 2 |
| 326 | regw | 1 |
| 327 | life.six | 1 |
| 328 | outcomes.six | 1 |
| 329 | senorx | 1 |
| 330 | ocay | 1 |
| 331 | separate-day | 1 |
| 332 | treatment-pathway | 1 |
| 333 | observational-study | 3 |
| 334 | reproduction-toxicology | 4 |
| 335 | nutrition-italy | 1 |
| 336 | adult-only | 1 |
| 337 | preparations.many | 1 |
| 338 | organism.laboratory | 1 |
| 339 | research/laboratory | 1 |
| 340 | four-city | 1 |
| 341 | initial-velocity | 1 |
| 342 | mid-to-high-quality | 1 |
| 343 | antimicrobial-susceptibility | 1 |
| 344 | outcomes.thirty | 1 |